Skip to main content
SpringerLink
Log in
Book cover

Malignant Pediatric Bone Tumors - Treatment & Management pp 83–107Cite as

Chemotherapy Regimens for Patients with Newly Diagnosed Malignant Bone Tumors

  • Chapter

Part of the book series: Pediatric Oncology ((PEDIATRICO))

Abstract

The advent of chemotherapy brought dramatic improvements to the care of patients stricken with malignant bone tumors. Early experimentation with cytotoxic medications identified a number of agents with activity in both Ewing’s sarcoma and osteosarcoma. Survival rates in patients treated with these new agents improved five- to six-fold over the course of less than a decade. Therapies identified during the early years of chemotherapy continue to form the backbone upon which most modern regimens are built. Efforts to further improve outcomes have proved difficult. Modest, incremental gains have come only through experimentation involving large populations of patients made possible through the emergence of international cooperative groups. Advances in supportive care have facilitated the gradual intensification of treatment regimens both in terms of dose intensity and interval compression. Patients with refractory or metastatic disease continue to fare poorly. New approaches to the treatment of these patients are desperately needed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Aljubran AH, Griffin A, Pintilie M, Blackstein M (2009) Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases. Ann Oncol 20:1136–1141. doi:10.1093/annonc/mdn731

    CAS  PubMed  Google Scholar 

  • Allison DC, Carney SC, Ahlmann ER et al (2012) A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012:704872. doi:10.1155/2012/704872

    PubMed Central  PubMed  Google Scholar 

  • Ambros IM, Ambros PF, Strehl S et al (1991) MIC2 is a specific marker for Ewing’s sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing’s sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 67:1886–1893

    CAS  PubMed  Google Scholar 

  • Anderson B (2005) Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. Pediatr Blood Cancer 44:584–588

    PubMed  Google Scholar 

  • Bacci G (2003) Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 14:1126–1134

    CAS  PubMed  Google Scholar 

  • Bacci G, Picci P, Ruggieri P et al (1990) Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 65:2539–2553

    CAS  PubMed  Google Scholar 

  • Bacci G, Picci P, Ferrari S et al (1993) Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 72:3227–3238

    CAS  PubMed  Google Scholar 

  • Bacci G, Picci P, Ferrari S et al (1998) Neoadjuvant chemotherapy for Ewing’s sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase – results of two sequential studies. Cancer 82:1174–1183

    CAS  PubMed  Google Scholar 

  • Bacci G, Mercuri M, Longhi A et al (2005) Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 41:2079–2085

    CAS  PubMed  Google Scholar 

  • Baum ES, Gaynon P, Greenberg L et al (1979) Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children’s Cancer Study Group Report. Cancer Treat Rep 63:1621–1627

    CAS  PubMed  Google Scholar 

  • Berrak SG, Pearson M, Berberoğlu S et al (2005) High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer 44:215–219

    PubMed  Google Scholar 

  • Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790

    PubMed  Google Scholar 

  • Bielack SS, Machatschek J-N, Flege S, Jürgens H (2004) Delaying surgery with chemotherapy for osteosarcoma of the extremities. Expert Opin Pharmacother 5:1243–1256. doi:10.1517/14656566.5.6.1243

    PubMed  Google Scholar 

  • Bielack S, Smeland S, Whelan J, Marina N (2013) MAP plus maintenance pegylated interferon alpha-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good. ASCO Proc

    Google Scholar 

  • Boye K, Del Prever AB, Eriksson M et al (2014) High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study. Pediatr Blood Cancer 61:840–845

    CAS  PubMed  Google Scholar 

  • Bramwell VH, Burgers M, Sneath R et al (1992) A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 10:1579–1591

    CAS  PubMed  Google Scholar 

  • Burdach S, Jürgens H, Peters C et al (1993) Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing’s sarcoma. J Clin Oncol 11:1482–1488

    CAS  PubMed  Google Scholar 

  • Burdach S, Van Kaick B, Laws HIJ et al (2000) Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and. Ann Oncol 11:1451–1462

    CAS  PubMed  Google Scholar 

  • Burgert BEO, Nesbit ME, Garnsey LA et al (1990) Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. J Clin Oncol 8:1514–1524

    PubMed  Google Scholar 

  • Casey DA, Wexler LH, Merchant MS et al (2009) Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 53:1029–1034. doi:10.1002/pbc.22206

    PubMed  Google Scholar 

  • Chou AJ, Kleinerman ES, Krailo MD et al (2009) Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer 115:5339–5348. doi:10.1002/cncr.24566

    CAS  PubMed Central  PubMed  Google Scholar 

  • Cortes EP, Holland JF, Wang JJ et al (1974) Amputation and adriamycin in primary osteosarcoma. N Engl J Med 291:998–1000. doi:10.1056/NEJM197411072911903

    CAS  PubMed  Google Scholar 

  • Craft A, Cotterill S, Bullimore J, Pearson D (1997) Long-term results from the first UKCCSG Ewing’s tumour study (ET-1). Eur J Cancer 33:1061–1069. doi:10.1016/S0959-8049(97)00043-9

    CAS  PubMed  Google Scholar 

  • Craft A, Cotterill S, Malcolm A (1998) Ifosfamide-containing chemotherapy in Ewing’s sarcoma: the Second United Kingdom Children’s Cancer Study Group and the Medical Research Council Ewing’s Tumor Study. Clin Oncol 16:3628–3633

    CAS  Google Scholar 

  • Cunningham D, Hawthorn J, Pople A et al (1987) Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet 1:1461–1463

    CAS  PubMed  Google Scholar 

  • Cupps RE, Ahmann DL, Soule EH (1969) Treatment of pulmonary metastatic disease with radiation therapy and adjuvant actinomycin D. Preliminary observations. Cancer 24:719–723. doi:10.1002/1097-0142(196910)24:4<719::AID-CNCR2820240409>3.0.CO;2-A

    CAS  PubMed  Google Scholar 

  • Dahlin DC, Coventry MB (1967) Osteogenic sarcoma: a study of six hundred cases. J Bone Joint Surg 49:101–110

    CAS  PubMed  Google Scholar 

  • Delépine N, Delépine G, Desbois J et al (1990) Osteogenic osteosarcoma: a model of curable disease by multidisciplinary approach of treatment. Biomed Pharmacother 44:243–248. doi:10.1016/0753-3322(90)90148-3

    PubMed  Google Scholar 

  • Deméocq F, Oberlin O, Benz-Lemoine E et al (1989) Initial chemotherapy including ifosfamide in the management of Ewing’s sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP). Cancer Chemother Pharmacol 24(Suppl 1):S45–S47

    PubMed  Google Scholar 

  • Donaldson SS, Torrey M, Link MP et al (1998) A multidisciplinary study investigating radiotherapy in Ewing’s sarcoma: end results of POG #8346. Int J Radiat Oncol 42:125–135. doi:10.1016/S0360-3016(98)00191-6

    CAS  Google Scholar 

  • Ebb D, Meyers P, Grier H et al (2012) Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J Clin Oncol 30:2545–2551

    CAS  PubMed Central  PubMed  Google Scholar 

  • Edmonson J, Green S, Ivins J et al (1984) A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 2:152–156

    CAS  PubMed  Google Scholar 

  • Eselgrim M, Grunert H, Kühne T et al (2006) Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer 47:42–50. doi:10.1002/pbc.20608

    PubMed  Google Scholar 

  • Ettinger LJ, Douglass HO, Higby DJ et al (1981) Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma. Cancer 47:248–254

    CAS  PubMed  Google Scholar 

  • Evans AE, Baehner RL, Chard RL et al (1974) Comparison of daunorubicin (NSC-83142) with adriamycin (NSC-123127) in the treatment of late-stage childhood solid tumors. Cancer Chemother Rep 58:671–676

    CAS  PubMed  Google Scholar 

  • Evans RG, Nesbit ME, Gehan EA et al (1991) Multimodal therapy for the management of localized Ewing’s sarcoma of pelvic and sacral bones: a report from the second intergroup study. J Clin Oncol 9:1173–1180

    CAS  PubMed  Google Scholar 

  • Ewing J (1924) Further report of endothelial myeloma of bone. Proc NY Pathol Soc 24:93–100

    Google Scholar 

  • Ferrari S, Mercuri M, Picci P et al (1999) Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori 85:458–464

    CAS  PubMed  Google Scholar 

  • Ferrari S, Smeland S, Mercuri M et al (2005) Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23:8845–8852. doi:10.1200/JCO.2004.00.5785

    PubMed  Google Scholar 

  • Finklestein JZ, Hittle RE, Hammond GD (1969) Evaluation of a high dose cyclophosphamide regimen in childhood tumors. Cancer 23:1239–1242

    CAS  PubMed  Google Scholar 

  • Fuchs N, Bielack SS, Epler D et al (1998) Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9:893–899

    CAS  PubMed  Google Scholar 

  • Goorin AM, Harris MB, Bernstein M et al (2002) Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 20:426–433. doi:10.1200/JCO.20.2.426

    CAS  PubMed  Google Scholar 

  • Goorin AM, Schwartzentruber DJ, Devidas M et al (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574–1580

    CAS  PubMed  Google Scholar 

  • Granowetter L, Womer R, Devidas M et al (2009) Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol 27:2536–2541. doi:10.1200/JCO.2008.19.1478

    CAS  PubMed Central  PubMed  Google Scholar 

  • Grier HE, Krailo MD, Tarbell NJ et al (2003) Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694–701. doi:10.1056/NEJMoa020890

    CAS  PubMed  Google Scholar 

  • Harris MB, Cantor AB, Goorin AM et al (1995) Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol 24:87–92

    CAS  PubMed  Google Scholar 

  • Hayes FA, Thompson EI, Meyer WH et al (1989) Therapy for localized Ewing’s sarcoma of bone. J Clin Oncol 7:208–213

    CAS  PubMed  Google Scholar 

  • Hunold A, Ahrens S, Boldering N (2004) Topotecan and cyclophosphamide for Ewing tumour relapse. SIOP Abstr. p O.025:333

    Google Scholar 

  • Hustu HO, Holton C, James D, Pinkel D (1968) Treatment of Ewing’s sarcoma with concurrent radiotherapy and chemotherapy. J Pediatr 73:249–251

    CAS  PubMed  Google Scholar 

  • Jaffe N, Farber S, Traggis D et al (1973) Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 31:1367–1373. doi:10.1002/1097-0142(197306)31:6<1367::AID-CNCR2820310611>3.0.CO;2-6

    CAS  PubMed  Google Scholar 

  • Jaffe N, Paed D, Traggis D et al (1976) Improved outlook for Ewing’s sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 38:1925–1930

    CAS  PubMed  Google Scholar 

  • James D, George P (1964) Vincristine in children with malignant solid tumors. J Pediatr 64:534–541

    PubMed  Google Scholar 

  • Jenkin RDT (1966) Ewing’s sarcoma a study of treatment methods. Clin Radiol 17:97–106. doi:10.1016/S0009-9260(66)80064-8

    CAS  PubMed  Google Scholar 

  • Juergens C, Weston C, Lewis I et al (2006) Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. 22–29. doi: 10.1002/pbc

  • Jürgens H, Exner U, Gadner H et al (1988) Multidisciplinary treatment of primary Ewing’s sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 61:23–32

    PubMed  Google Scholar 

  • Jürgens H, Exner U, Kühl J et al (1989) High-dose ifosfamide with mesna uroprotection in Ewing’s sarcoma. Cancer Chemother Pharmacol 24(Suppl 1):S40–S44

    PubMed  Google Scholar 

  • Kager L, Zoubek A, Pötschger U et al (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21:2011–2018

    PubMed  Google Scholar 

  • Kalam K, Marwick TH (2013) Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 49:2900–2909

    CAS  PubMed  Google Scholar 

  • Khanna C, Fan TM, Gorlick R et al (2014) Towards a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res. doi:10.1158/1078-0432.CCR-13-2574

    Google Scholar 

  • Kudawara I, Aoki Y, Ueda T et al (2013) Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. J Chemother 25:41–48. doi:10.1179/1973947812Y.0000000055

    CAS  PubMed  Google Scholar 

  • Kushner BH, Meyers PA (2001) How effective is dose-intensive/myeloablative therapy against Ewing’s sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 19:870–880

    CAS  PubMed  Google Scholar 

  • Le Deley M-C, Delattre O, Schaefer K-L et al (2010) Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 28:1982–1988. doi:10.1200/JCO.2009.23.3585

    PubMed  Google Scholar 

  • Lewis IJ, Nooij MA, Whelan J et al (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99:112–128. doi:10.1093/jnci/djk015

    CAS  PubMed  Google Scholar 

  • Link MP, Goorin AM, Miser AW et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600–1606. doi:10.1056/NEJM198606193142502

    CAS  PubMed  Google Scholar 

  • Lipshultz SE, Lipsitz SR, Mone SM et al (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738–1743. doi:10.1056/NEJM199506293322602

    CAS  PubMed  Google Scholar 

  • Lipshultz SE, Miller TL, Lipsitz SR et al (2012) Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics 130:1003–1011. doi:10.1542/peds.2012-0727

    PubMed Central  PubMed  Google Scholar 

  • Marcove RC, Mike V, Hajek JV et al (1970) Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J Bone Joint Surg 52:411–423

    CAS  PubMed  Google Scholar 

  • Marina N, Smeland S, Bielack SS, et al. (2014) MAPIE vs MAP as postoperative chemotherapy in patients with a poor response to preoperative chemotherapy for newly-diagnosed osteosarcoma: results from EURAMOS-1. Connect. Tissue Oncol Soc. Berlin, Germany, p 96

    Google Scholar 

  • Marti C, Kroner T, Remagen W et al (1985) High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 69:115–117

    CAS  PubMed  Google Scholar 

  • McKeon C, Thiele CJ, Ross RA et al (1988) Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing’s sarcoma and neuroepithelioma. Cancer Res 48:4307–4311

    CAS  PubMed  Google Scholar 

  • Meyer WH, Kun L, Marina N et al (1992) Ifosfamide plus etoposide in newly diagnosed Ewing’s sarcoma of bone. J Clin Oncol 10:1737–1742

    CAS  PubMed  Google Scholar 

  • Meyers PA, Gorlick R, Heller G et al (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16:2452–2458

    CAS  PubMed  Google Scholar 

  • Meyers PA, Krailo MD, Ladanyi M et al (2001) High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not improve. J Clin Oncol 19:2812–2820

    CAS  PubMed  Google Scholar 

  • Meyers PA, Schwartz CL, Krailo M et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004–2011. doi:10.1200/JCO.2005.06.031

    CAS  PubMed  Google Scholar 

  • Meyers PA, Schwartz CL, Krailo MD et al (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival–a report from the Children’s Oncology Group. J Clin Oncol 26:633–638. doi:10.1200/JCO.2008.14.0095

    CAS  PubMed  Google Scholar 

  • Miser J, Kinsella T, Triche T et al (1987a) Treatment of peripheral neuroepithelioma in children and young adults. J Clin Oncol 5:1752–1758

    CAS  PubMed  Google Scholar 

  • Miser JS, Kinsella TJ, Triche TJ et al (1987b) Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5:1191–1198

    CAS  PubMed  Google Scholar 

  • Mosende C, Gutierrez M, Caparros B, Rosen G (1977) Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcoma. Cancer 40:2779–2786. doi:10.1002/1097-0142(197712)40:6<2779::AID-CNCR2820400604>3.0.CO;2-E

    CAS  PubMed  Google Scholar 

  • Müller CR, Smeland S, Bauer HCF et al (2005) Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol 44:475–480

    PubMed  Google Scholar 

  • Mulrooney DA, Yeazel MW, Kawashima T et al (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606

    PubMed Central  PubMed  Google Scholar 

  • Nesbit ME, Perez CA, Tefft M et al (1981) Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: an Intergroup Study. Natl Cancer Inst Monogr 56:255–262

    PubMed  Google Scholar 

  • Nesbit MEJ, Gehan E, Burgert EOJ et al (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 8:1664–1674

    PubMed  Google Scholar 

  • Oberlin O, Habrand JL, Zucker JM et al (1992) No benefit of ifosfamide in Ewing’s sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 10:1407–1412

    CAS  PubMed  Google Scholar 

  • Ochs JJ, Freeman AI, Douglass HO et al (1978) cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 62:239–245

    CAS  PubMed  Google Scholar 

  • Oldham RK, Pomeroy TC (1972) Treatment of Ewing’s sarcoma with adriamycin (NSC-123127). Cancer Chemother Rep 56:635–639

    CAS  PubMed  Google Scholar 

  • Paulussen M, Ahrens S, Dunst J et al (2001) Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol 19:1818–1829

    CAS  PubMed  Google Scholar 

  • Phillips RF, Higinbotham NL (1967) The curability of Ewing’s endothelioma of bone in children. J Pediatr 70:391–397. doi:10.1016/S0022-3476(67)80136-7

    CAS  PubMed  Google Scholar 

  • Picci P, Bacci G, Campanacci M et al (1985) Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 56:1515–1521

    CAS  PubMed  Google Scholar 

  • Pinkel D (1962) Cyclophosphamide in children with cancer. Cancer 15:42–49

    CAS  PubMed  Google Scholar 

  • Provisor A, Ettinger L, Nachman J et al (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 15:76–84

    CAS  PubMed  Google Scholar 

  • Rosen G (1985) Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics 8:659–664

    CAS  PubMed  Google Scholar 

  • Rosen G, Wollner N, Tan C et al (1974) Disease-free survival in children with Ewing’s sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer 33:384–393

    CAS  PubMed  Google Scholar 

  • Rosen G, Caparros B, Mosende C et al (1978) Curability of Ewing’s sarcoma and considerations for future therapeutic trials. Cancer 41:888–899

    CAS  PubMed  Google Scholar 

  • Rosen G, Caparros B, Huvos AG et al (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230

    CAS  PubMed  Google Scholar 

  • Saeter G, Alvegård TA, Elomaa I et al (1991) Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 9:1766–1775

    CAS  PubMed  Google Scholar 

  • Saylors RL, Stine KKC, Sullivan J, et al. (2001) Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19:3463–3469

    CAS  PubMed  Google Scholar 

  • Scheef W, Klein HO, Brock N et al (1979) Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep 63:501–505

    CAS  PubMed  Google Scholar 

  • Schwartz HS, Sodergren JE, Sternberg SS, Philips FS (1966) Actinomycin D: effects on Ridgway osteogenic sarcoma in mice. Cancer Res 26:1873–1879

    CAS  PubMed  Google Scholar 

  • Schwartz HS, Sodergren JE, Ambaye RY (1968) Actinomycin D: drug concentrations and actions in mouse tissues and tumors. Cancer Res 28:192–197

    CAS  PubMed  Google Scholar 

  • Smeland S, Müller C, Alvegard TA et al (2003) Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39:488–494

    CAS  PubMed  Google Scholar 

  • Smith MA, Ungerleider RS, Horowitz ME, Simon R (1991) Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing’s sarcoma. J Natl Cancer Inst 83:1460–1470

    CAS  PubMed  Google Scholar 

  • Souhami RL, Craft AW, Van der Eijken JW et al (1997) Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350:911–917. doi:10.1016/S0140-6736(97)02307-6

    CAS  PubMed  Google Scholar 

  • Sutow WW (1968) Vincristine (NSC-67574) therapy for malignant solid tumors in children (except Wilms’ tumor). Cancer Chemother Rep 52:485–487

    CAS  PubMed  Google Scholar 

  • Sutow W, Sullivan M (1962) Cyclophosphamide therapy in children with Ewing’s sarcoma. Cancer Chemother Rep 23:55–60

    CAS  PubMed  Google Scholar 

  • Sutow WW, Vietti TJ, Fernbach DJ et al (1971) Evaluation of chemotherapy in children with metastatic Ewing’s sarcoma and osteogenic sarcoma. Cancer Chemother Rep 55:67–78

    CAS  PubMed  Google Scholar 

  • Sutow WW, Sullivan MP, Wilbur JR, Cangir A (1975) Study of adjuvant chemotherapy in osteogenic sarcoma. J Clin Pharmacol 15:530–533. doi:10.1002/j.1552-4604.1975.tb01476.x

    CAS  PubMed  Google Scholar 

  • Taylor W, Ivins J, Dahlin D et al (1978) Trends and variability in survival from osteosarcoma. Mayo Clin Proc 53:695–700

    CAS  PubMed  Google Scholar 

  • Taylor W, Ivins J, Pritchard D et al (1985) Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc 60:91–104

    CAS  PubMed  Google Scholar 

  • Thompson J, George EO, Poquette CA et al (1999) Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 5:3617–3631

    Google Scholar 

  • Turc-Carel C, Philip I, Berger M-P et al (1983) Chromosomal translocations in Ewing’s sarcoma. N Engl J Med 309:496–498. doi:10.1056/NEJM198308253090817

    Google Scholar 

  • Van Dalen EC, Caron HN, Dickinson HO, Kremer LCM (2005) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev (2):CD003917

    Google Scholar 

  • Von Hoff DD (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710

    Google Scholar 

  • Wagner L, McAllister N (2007) Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood 48:132–139. doi:10.1002/pbc

    Google Scholar 

  • Wagner LM, Crews KR, Iacono LC et al (2004) Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 10:840–848. doi:10.1158/1078-0432.CCR-03-0175

    CAS  PubMed  Google Scholar 

  • Weinfeld MS, Dudley HR Jr (1962) Osteogenic sarcoma a follow-up study of the ninety-four cases observed at the Massachusetts general hospital from 1920 to 1960. J Bone Joint Surg 44:269–276

    PubMed  Google Scholar 

  • Whang-Peng J, Triche TJ, Knutsen T et al (1984) Chromosome translocation in peripheral neuroepithelioma. N Engl J Med 311:584–585. doi:10.1056/NEJM198408303110907

    CAS  PubMed  Google Scholar 

  • Winkler K, Beron G, Kotz R et al (1983) Adjuvant chemotherapy in osteosarcoma – effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study. J Cancer Res Clin Oncol 106(Suppl):1–7

    PubMed  Google Scholar 

  • Winkler K, Beron G, Kotz R et al (1984) Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 2:617–624

    CAS  PubMed  Google Scholar 

  • Winkler K, Beron G, Delling G et al (1988) Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329–337

    CAS  PubMed  Google Scholar 

  • Winkler K, Bielack S, Delling G et al (1990) Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer 66:1703–1710

    CAS  PubMed  Google Scholar 

  • Womer R, Daller R, Fenton JG, Miser J (2000) Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing’s sarcomas and soft tissue sarcomas in children. Eur J Cancer 36:87–94. doi:10.1016/S0959-8049(99)00236-1

    CAS  PubMed  Google Scholar 

  • Womer RB, West DC, Krailo MD et al (2012) Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30:4148–4154. doi:10.1200/JCO.2011.41.5703

    CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology/BMT, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH, 43205, USA

    Ryan D. Roberts MD, PhD & Bhuvana A. Setty MD

  2. Department of Pediatrics, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH, 43205, USA

    Mary Frances Wedekind MD

Authors
  1. Ryan D. Roberts MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary Frances Wedekind MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bhuvana A. Setty MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryan D. Roberts MD, PhD .

Editor information

Editors and Affiliations

  1. Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children’s Hospital, Columbus, Ohio, USA

    Timothy P. Cripe

  2. Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children’s Hospital, Columbus, Ohio, USA

    Nicholas D. Yeager

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Roberts, R.D., Wedekind, M.F., Setty, B.A. (2015). Chemotherapy Regimens for Patients with Newly Diagnosed Malignant Bone Tumors. In: Cripe, T., Yeager, N. (eds) Malignant Pediatric Bone Tumors - Treatment & Management. Pediatric Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18099-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18099-1_6

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18098-4

  • Online ISBN: 978-3-319-18099-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation